Management of Severe Fatigue in Pulmonary Sarcoidosis
Understanding Sarcoidosis-Associated Fatigue
- Fatigue is extremely common in sarcoidosis, affecting up to 90% of patients, and significantly reduces quality of life 4
- Fatigue may persist for years even after apparent remission of active granulomatous inflammation 4
- There is often poor agreement between physicians' and patients' assessment of fatigue severity, highlighting the importance of using validated patient-reported outcome measures 4
Initial Assessment
- Before attributing fatigue to sarcoidosis, rule out other potential causes, including metabolic disorders, mental health conditions, sleep disorders, small fiber neuropathy, and vitamin D deficiency 4
Treatment Algorithm
First-Line Approach: Non-Pharmacological Interventions
- A pulmonary rehabilitation program for 6-12 weeks is recommended as first-line treatment, which has shown significant improvements in fatigue and exercise capacity 1, 2, 3
- Inspiratory muscle strength training for 6 weeks leads to significant improvements in maximal inspiratory and expiratory pressure and exercise capacity 1, 2, 3
Second-Line Approach: Pharmacological Interventions
- D-methylphenidate may be used if fatigue persists despite rehabilitation efforts, with a trial for 8 weeks to assess effect and tolerability, and has shown 36% improvement in fatigue in randomized trials 1, 2, 3
- Armodafinil may be used as an alternative, with initial dose of 150 mg daily, and has demonstrated improvement in fatigue as measured by FAS and FACIT-F scores, but monitor for side effects similar to methylphenidate 1, 2, 3, 5
Monitoring and Follow-up
- Evaluate functional improvement with 6-minute walk test 2